Brisbane Cancer Conference Program, 29-30\textsuperscript{th} November 2018
Brisbane Convention and Exhibition Centre
29-30\textsuperscript{th} November, 2018

29\textsuperscript{rd} November 2018
Thursday Morning Symposia

Breast cancer symposium (supported by Novartis) - Boulevard Room

\textbf{Chairs:} Rik Thompson; Katharine Cuff, Georgia Chenevix Trench

Genomics, prognostic factors and novel targets for therapy
8.00am – Germline events underlining breast cancer – Jonathan Beesley
8.20am – Somatic mutations in breast cancer – Peter Simpson
8.40am – Mammographic density in breast cancer – Honor Hugo
9.00am – Combining targeted therapies with immunotherapies – Fiona Simpson
9.20am – CDCA3 in breast cancer: prognostic factor and therapeutic target– Mark Adams
9.40am – Targeting PARP in breast cancer – Vladimir Andelkovic
10-10.30am Morning Tea

Translating science into precision medicine in breast cancer
10.30am - CDK4/6: from the bench to the bedside – Nicole McCarthy
10.50am - PI3K mutation targeted agents in breast cancer – Kathryn Middleton
11.10am - Immunotherapy in breast cancer: recent advances and the future – Jasotha Sanmugarajah
11.30am – The SAFE trial: ‘ideal/highly supervised’ exercise vs that in the real world – Sandi Hayes
11.50am Discussion

Prostate cancer (supported by Janssen) – B1 and 2

\textbf{Chairs:} Colleen Nelson, Ian Vela, Elizabeth Williams

8.00am – Prostate cancer genomics in metastatic disease - Chris Hovens
8.20am - BRAC2 cohorts and relationship to intraductal prostate cancer - Damian Bolton
8.40am - PSA SNPs: clinical relevance – Jyotsna Batra
9.00am – Preclinical models of prostate cancer – Elizabeth Williams
9.20am - Liquid biopsies in prostate cancer – Matt Trau
9.40am – Neuropilin-1 a prognostic factor and target for therapy - Brett Hollier
10.00am Morning Tea
10.30am - Robotic vs standard surgery for prostate cancer – John Yaxley
11.00am – Translation of recent advances in the biology of prostate cancer into therapy: targeting the androgen receptor, homologous recombination and the immune response – Arun Azad
11.40am - Low dose testosterone for management of ADT toxicity - Handoo Rhee
11.50am Discussion

Immuno-oncology (supported by Astrazeneca) – B3

\textbf{Chairs:} Riccardo Dulcetti, Rajiv Khanna

8.00am - Evolving understanding of immuno-biology in malignant disease – Mark Smyth
8.40am – Innate immunity and immunotherapy – Tobias Bald
9.00am – Recent advances in cancer vaccines – Riccardo Dolcetti
9.20am - Recent advances in lung cancer immunotherapy – Barbara Melosky
9.40am – Biomarkers predict efficacy of Immunotherapy – Wendy Cooper
10.00am – Radiotherapy enhances immunotherapy: fact or fiction – Ben Chua
10.30am – Clinical factors predicting benefit from immunotherapy – Rebecca Moor
11.00am – Update on immunotherapy in the MoST trial – David Thomas
11.30am – Adoptive T-cell therapies in oncology – Rajiv Khanna

Survivorship (supported by Menarini) – Boulevard theatre
Title: Queensland cancer survivorship collaborative concept development workshop
Faculty Members: Liz Eakin, Jane Turner, Geoff Mitchell, Louisa Gordon, David Wyld, Lee Jones, Ray Chan
8.00am - A two phase study to develop, implement and evaluate a pilot model of post-treatment specialist multidisciplinary survivorship care for adolescents and young adults living with cancer across Queensland – Lucy Holland
9.00am - AMBER: Addressing Modifiable Health Behaviours and Cancer Late Effects in Children and Adolescents – Dr Natalie Bradford
10.00am Morning Tea
10.30am - The psychosocial needs of younger female breast and gynaecological cancer survivors - Mingshuang Ding
11.00am – Retrospective-prospective cohort study of patients treated with chemotherapy and/or immunotherapy known to cause cardiac dysfunction – Penelope Stevens
11.30am Discussion

12.00pm – Roche Sponsored lunch

12.30pm - Lunch-time symposium (supported by Roche) – Boulevard Auditorium
12.30pm - Targeted therapies in solid tumours: expanding opportunities – Chee Lee
1.00pm - What have we learnt about immunotherapy this year? – TBC

1.30Pm – Arrival refreshments

Plenary Thursday pm – Boulevard Auditorium
Session 1
Chairs: Damian Topp; David Bunker
2.00pm - Vision for Oncology Diagnostics in Queensland - Keith McNeill
2.20pm - Evolution of genomics into cancer care and research - Sunil Lakhani
2.40pm - Germline cancer risk tsunami; are we ready yet? – Aideen McInerney-Leo

Session 2
Chairs: Janet Hardy; Leanne Stone
3.00pm - Impact of novel therapies of integration of palliative medicine into cancer care – Carol Douglas
3.30pm - Marijuana – the herbal medicine for everyone and everything? – Philip Goode

4.00pm – Tea and Coffee

Thursday Workshops
Imaging - Arbour level, Room A1
Co-ordinators: Paul Thomas, Pam Russell, Tom Lloyd
16.30 - Potential applications of 7T MRI in cancer imaging - Markus Bath
16.50 - Clinical experience of PET/MR in oncology - Philip Law
17.10 - Multimodality imaging for assessment of prostate cancer metastases in mice - Brian Tse
17.30 - Imaging of perineural spread in head and neck cancer - Jennifer Sommerville
17.50 - Theranostics and prostate cancer - David Pattison
18.10 - Breast MRI to predict treatment response to neoadjuvant chemotherapy - Gorane Santamaria

Commercialisation – Arbour level, Room A2
‘Fire-side chat forum’
Moderators: Lyn Griffiths, Derek Richards
- Cherrell Hirst, Chairperson, Factor Therapeutics
- Peter Tapley, pre-clinical toxicology, TetraQ
- Mark Reid, Clinical Regulations Consultant, Graythan Regulatory Services
- Les Tillack, Biologics manufacturing in bacteria, Lunabio
- TBC, Biologics manufacturing in mammalian cells, Patheon
- TBC, CEO, Vaccines, Admedus

Clinical trials – B1
Chairs: Adam Stoneley; Suzanne Elliott
4.30pm - Queensland Health Tele-Trials Update - Roberta Lusa
Snapshot Profiles of Our Cancer Trials Units
- Size, structure and staffing model of trials unit
- Brief overview of clinical trial portfolio
- Special features & point of difference
4.45pm - Gallipoli Medical Research Foundation – Suzanne Elliott
4.55pm – Princess Alexandra Hospital - Adrienne See
5.05pm – Pindara Hospital – Andrew McFadden
5.15pm – Sunshine Coast Unviersity Hospital – Helen Rodgers
5.25pm – University of Sunshine Coast – Lucas Litewka
5.35pm – Genesis Cancer Care – Vicki Sproule
5.45pm - Gold Coast University Hospital – Jacob Darch
5.55pm – Royal Brisbane & Women’s Hospital – Robyn Western & Annette Cubitt
6.05pm – Mater Adult Hospital – Matthew Spitzer
6.15pm – Lady Cilento Children’s Hospital – Amy Smalley
6.25pm – Sunshine Coast University Hospital – Helen Rodgers
6.35pm – Icon Cancer Centre – Adam Stoneley

Genomics – Boulevard level B2
Chairs: Nic Waddell, John Pearson
4.30pm - Cancer Genomics, Australian Translational Genomics Centre – Matthew Brown
4.50pm - The ICCon project - Uwe Dressel & Aimee Davidson
5.10 pm - Implementation project: Queensland Myeloid Genomics Program - Nicholas Weber
5.30pm - QGHA Genomic Information Management - Alejandro Metke
5.50pm - Implementing gene curation for hereditary cancer susceptibility in Australia: achieving consensus on genes with clinical utility - Emma Tudini
6.10pm - Discussion
Palliative Medicine – Boulevard level B3

Chairs: Janet Hardy, Leanne Stone

4.30pm - The factors associated with non-beneficial treatment at the end-of-life - Hannah Carter

4.45pm - Expenditure for investigations undertaken on patients approaching end-of-life - Gauri Gogna

5.00pm - Talking death - Rebecca Olson

5.15pm - Challenges in adolescent palliative care - Christine Mott

5.30pm - QT prolongation in palliative care patients - Jessica Cross

5.45pm - Holistic needs assessment of children admitted to Hummingbird house - Leigh Donovan

7.00pm ‘til late – Gala Dinner, Sky Room, Brisbane Convention and Exhibition Centre

30th November 2018

Plenary Friday am – Boulevard Auditorium

Chairs: TBC, Allison Pettit

8.00am - Whole genome sequencing from EBUS FNAs of lung cancer - David Fielding

8.20am - Novel liquid biopsies in cancer care – Matt Trau

8.40am - Management of oligo-metastatic disease: Radiotherapy perspective – David Prior

9.00am - Updates on Trans-oral robotic surgery: Where to Next? - Sam Dowthwaite

9.20am - Supportive care needs: proof, provision and practice - Vanessa Beesley

9.40am – Big data – importance for out-patient nursing – Nina Simpson

10.00am – Tea and Coffee

Friday am workshops

Brain tumours - A1

Chair: Mark Pinkham

10.30am - Comparative neuro-oncology network - Simon Puttick

10.40am - Speech and language outcomes in adults and children following treatment for primary brain tumours - Greig de Zubicaray

10.50am - Glioma heterogeneity - Seckin Akgul

11.00am - Powering and arming the immune system to combat Glioblastoma - Roberta Mazzieri

11.10am - Deregulation of differentiation in glioma - Jens Bunt

11.20am - Brain tumour theranostics - Kevin Lee

11.30am - Discussion

Novel Immunotherapies - A2

Chairs: Rajiv Khanna; Riccardo Dulcetti

- Analysis for Tumour Mutation Burden in tumours - Paul Leo

- Lesson from HPV-driven carcinogenesis - Kelvin Tuong

- Cross-presenting dendritric cell therapy in solid tumours - Kristen Radford

- Glioblastoma immunotherapy - Corey Smith

- Targeting the tumour microenvironment - Roberta Mazzieri

- Checkpoint Immunotherapy - Indrajit Das

- Neoadjuvant pembrolizumab plus denosumab in lung cancer – TBC
Thoracic Malignancies - B1

Chairs: Brett Hughes, Simon Bowler, Nic Waddell

2.30pm Optimising Clinical Care and Research for the delivery of Precision Medicine in Thoracic Malignancies in Queensland
- Tissue collection and biobanking
- ‘Omics/bioinformatics
- Liquid biopsies
- DNA repair
- Screening & Imaging
- Clinical trials portfolio including targeted therapies and immunotherapy
- Telemedicine
- Palliative medicine
- Survivorship - Ray Chan

Panel members: David Fielding, Ray Chan, Derek Richard, Abishek Joshi, Matt Trau, Chamindie Punyadeera, Andreas Voeller, Matt Brown, John Pearson, Aideen McInerney-Leo

Pharmacy – B2

Chairs: Dan McKavanagh; Emily Went

10.30am - Developing a procurement guide for oncology and related pharmaceuticals – Michael Powell
0.45am - Scaling Cancer Pharmacy Education to Meet the Needs of an International Workforce - Courtney Oar
11.00am - Implementation of a Quality Assurance Framework for Oncology Pharmacy Practice within a National Pharmacy Network - Chris Giles
11.15am - Ramsay CHARM Rollout – A Pharmacist-Led Adventure in Managing Organisational & Systems Change - Jameson Fawns
11.30am – Activity based funding: funding the pharmacist - Christine Carrington
11.45am - Discussion

GU malignancies – B3

Chairs: Jeff Goh, Andrew Hadley

Clinical and Translational research in GU malignancies in Queensland
10.30pm – Advances in renal cell cancer care – Jeff Goh
10.40pm – Bladder
- Overview of bladder cancer - Aneta Suder (5 mins)
- Biomarkers for bladder cancer – Prahast Kumar (15 mins)
11.10pm - Prostate cancer
- Advances in Prostate Cancer therapy – Jeff Goh (15 mins)
- Theranostics in prostate cancer – Pam Russell & Kevin Lee (15 mins)
- Inhibiting resistance mechanisms in PTEN-deficient prostate cancer – David Waugh (15 mins)
11.55pm - Discussion: Future studies

Gynae-oncology – Boulevard room

Chairs: A/Prof Lewis Perrin & Prof John Hooper

10.30am - Evaluating hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer
- Sinead Barry
10.44am - Pharmacological intervention opportunities for HPV related gynaecological cancers - Brian Gabrielli
10.58am - Harnessing the immune system for ovarian cancer treatment - Sherry Wu
11.12am - Bariatric surgery and endometrial cancer trial - Kate O’Hare
11.26am - Recent trials including potential of immune checkpoint therapies for gynaecological cancers - Jim Coward
11.40 – Clinical utility in ovarian cancer of HR defects in breast cancer - Nic Waddell
11.45am - Discussion

12.00pm – Tea and Coffee

Plenary Friday lunch-time – Boulevard auditorium
Chairs: Frank Gannon; Paul Harkin
12.30pm - Skin cancer screening – Peter Soyer
12.50 pm - Advances in systemic therapy of head and neck cancer – Brett Hughes
1.10pm - Tumour mutation burden and cancer immunotherapy – Kenneth O’Byrne
1.30pm - Future care of rare tumours – David Thomas

2.00pm – Tea and Coffee

Small 3D cancer models - A1
Chairs: Laura Bray, Nathalie Bock
2:30pm - 3D Models Coupled with Live Cell Imaging to Study Dynamic Melanoma Invasion – Robert Ju
2:40pm - 3D prostate cancer models: strategies, insights and artefacts - Michael Doran
2:50pm - Assessment of cellular signalling in an organoid model of normal mammary gland development - Teneale Stewart
3:00pm - Modelling chemo-resistance in non-small lung cancer utilising a novel 3D cell culture technology - Sarah-Louise Ryan
3:10pm - Making Organoids - Lessons Learned from Cardiac Organoid Bioengineering - James Hudson
3:20pm- Using ex vivo culture to assess patient therapy response - Tashbib Khan
3:30pm - A 3D model of osteoblastic stimulation by prostate cancer - Anthony Atack
3:40pm - Engineering a human bone metastatic microenvironment in vitro for therapy assessment - Nathalie Bock

Breast cancer - A2
Emerging themes and projects in Brisbane
Chairs: Rik Thompson, Sunil Lakhani
- Radiation oncology trials – Nicola Lowrey
- Q-IMPROvE – Amy McCart-Reed
- CRISP-R: Applications in breasts cancer - Sefi Rosenbluh
- Epithelial Mesencymal Transition – Andy Redfern
- Consumer input – Leonie Young

Melanoma and skin cancer - B1
Chairs: Mitchell Stark, Loredana Spoerri
2.30-2.40pm - Different genetic mechanisms mediate spontaneous versus UVR-induced malignant melanoma - Blake Ferguson
2.40 - Development of a spider peptide as a therapeutic to treat metastatic melanoma - Sónia Henriques
2.50 - Genomics and biological correlates of radiomics in melanoma - Lauren Aoude
3.00 - Characterising the unique oncogenic signalling of uveal melanoma - Kelly Brooks
3.10 - CHK1 inhibitor + low dose hydroxyurea effectively controls melanoma growth and triggers immunostimulatory signals without significant myelosuppression - Martina Proctor
3.20 - Distinct roles for host and tumor intrinsic CD155 in tumor growth and metastasis - Indrajit Das
3.30 - Microtubule-Dependent Mechanosensing in Cell Migration and Cancer Invasion - Sam Stehbens
3.40 - Dissecting transcriptional drivers of melanoma plasticity: can we block melanomas escape route? - Aaron Smith
3.50 - Functional analysis of MTAP haplotypes in melanoma risk - Rick Sturm

**Head and neck cancer - B2**

**Chair:** Chris Perry
2.30pm - Overview of clinical trials in head and neck cancer in Queensland – Rahul Ladwa
2.40pm - Oral HPV infection, head and neck cancer and sexual behavior – Annika Anttonnson
2.50pm - Introduction to Barcoding for HPV Oropharyngeal Cancer - Jazmina Gonzales Cruz
3.00pm - Pathos Trial and de-escalation of HPV Head and Neck Cancer Treatment - Liam Masterton
3.10pm - Circulating tumour cells in head and neck cancer - Arutha Kalusinghe
3.20pm - Adenoid Cystic Carcinoma in Queensland – Fiona Simpson
3.30pm - CXCR in head and Neck Cancer – Sarju Vasani
3.40pm - Discussion

**GI malignancies – B3**

**Chairs:** Chris Gillespie, Vikram Jain
2.30pm – The use of MRI as a prognostic indicator in rectal cancer – Kate MacLean
2.40pm – Biomarkers predicting pathological complete response in rectal cancer - Joseph Kong
2.40pm – Appendiceal tumours: lessons to be learnt from an audit of outcomes in Queensland - Hussain Al-Khdhur
2.50pm – Outcomes of pelvis exenteration in a centralized service – David Taylor
3.00pm – Discussion
3.10pm – Studies in colorectal cancer at RBWH: Matt Burge
  - Circulating tumor DNA analysis informing adjuvant chemotherapy in stage III colon cancer: a multicenter phase II/III randomized controlled study (DYNAMIC-III)
  - Enhancing immunotherapy in colorectal cancer: an RBWH study
3.30pm - Regorafenib and aspirin, a phase I/II study – Rahul Ladwa
3.40pm – Potential use of SABR for hepatocellular cancer – David Pryor
3.50pm - Discussion

**Survivorship - Boulevard Room**

**Title:** Patient Reported Outcomes in Routine Care Queensland (Panel Discussion)

**Chairs:** Ray Chan; David Wyld
2.30-4.00pm What is the future of PRO in routine care? How can we synergise to make sure we get the biggest bang for our buck?
Panel: Leanne Stone, Bena Cartmill, Melissa Eastgate, Natasha Roberts, Danica Cassio, Penny Webb, Daniel Mckavanagh and Natalie Bradford

4.00pm – Refreshment Break
Plenary Friday evening - Boulevard Auditorium
GATTACA

Chairs: Michael Cleary; Keith McNeill
4.10pm - Siemens AI program in oncology - Confirmed
4.30pm – Genomics and AI – Nicholas Therkelsen-Terry
4.50pm - Discussion

5.15pm Wine and Cheese

6.00pm Exit